Prostate cancer screening now means a PSA blood test every two years for average-risk men ages 50 to 69, the American Cancer Society said November 12, 2026. The interval is new. What a man pays for the test is not settled by the guideline at all, because a screening recommendation and an insurance benefit are two different documents.
The American Cancer Society (ACS) issued its updated prostate cancer early-detection guideline on November 12. KFF Health News summarized the change the next morning, November 13. The scheduled interval changes the clinical recommendation for average-risk men, but it does not rewrite an insurance contract or establish a new federal coverage requirement.
ACS GUIDELINE: RECORDED SCREENING SCHEDULES
Earlier ACS guidance emphasized shared decision making and set no fixed interval for average-risk men. News coverage of the change described the previous approach as leaving average-risk testing to individual discretion after a risk discussion. The updated guideline specifies intervals by age and risk category.
| Recorded Risk Group | Starting Age and Interval |
|---|---|
| Average risk | Ages 50 through 69: PSA test every 2 years |
| Black men | Begin at 45; PSA test every year through age 69 |
| Non-Black men with a close relative diagnosed before age 65, or more than one close relative with prostate cancer | Begin at 45; PSA test every year through age 69 |
| Non-Black men with one close relative diagnosed at age 65 or older | Begin at 45; PSA test every 2 years through age 69 |
| Inherited gene changes, such as BRCA2 | Discuss screening timing and interval with a clinician |
| Ages 70 to 74 | Discuss whether to continue; if screening continues, test every 2 years |
| Age 75 and older | ACS does not recommend screening; very healthy men ages 75 to 79 may discuss continuing, especially with rising PSA. Screening is discouraged after 80. |
| Poor health at any age with life expectancy under 10 years | Screening is not recommended |
A close relative for the family-history schedule means a father, brother, or son. ACS does not recommend a digital rectal exam (DRE) as a screening test, although it may be used during a diagnostic workup.
If PSA is 3 ng/mL or higher in a man younger than 70, or 6.5 ng/mL or higher in a man 70 or older, the guideline says the result should be repeated, preferably 2 weeks to 3 months later. If it remains high, most men should receive a prostate MRI and/or biomarker test before biopsy. For low-risk prostate cancer, active surveillance should be offered as the initial option.
COVERAGE GAP: A GUIDELINE IS NOT A COVERAGE DETERMINATION
The federal no-cost preventive-services rule under the Affordable Care Act generally applies to services receiving a U.S. Preventive Services Task Force (USPSTF) A or B grade. The Task Force’s current final prostate cancer screening recommendation is unchanged from 2018: an individual decision for men ages 55 to 69, graded C, and a recommendation against screening for men 70 and older, graded D.
A C grade means coverage for PSA screening is a plan-design question, not a federal requirement for no-cost coverage. Plans may cover screening and may apply cost sharing. The plan’s terms govern. State requirements may also differ by plan type and location. The USPSTF update for this topic remains in progress, and a future final recommendation could change the preventive-coverage framework.
The coding distinction is also material. A PSA test ordered for an asymptomatic man as screening may or may not have cost sharing under the plan. Once a result is abnormal, or symptoms are present, repeat testing and follow-up are diagnostic services. Deductibles, coinsurance, network rules, and medical-necessity requirements may then apply.
TYPICAL COST-SHARING PATH
| Service Stage | Commercial Coverage | Medicare Coverage | Medicaid Coverage |
|---|---|---|---|
| Screening PSA test | May be covered with cost sharing; confirm preventive classification and plan terms | Part B covers the PSA blood test once every 12 months for eligible men over 50; the test itself costs nothing | Coverage and cost sharing depend on the state program and benefit rules; confirm with the plan |
| Repeat PSA after an abnormal result | Generally treated as diagnostic; deductible or coinsurance may apply | Coverage and cost sharing depend on the service and applicable Medicare rules; confirm with the plan | Generally depends on state coverage and applicable cost-sharing rules |
| Prostate MRI and/or biomarker test | Often subject to network, authorization, deductible, or coinsurance rules | Coverage and cost sharing vary by service and plan; Medicare Advantage may apply network and prior-authorization rules | Coverage and authorization rules vary by state and service |
| Prostate biopsy | Generally diagnostic, with cost sharing based on plan terms and network status | May involve cost sharing based on setting and coverage; confirm provider and facility rules | Coverage and cost sharing vary by state and provider |
| Treatment or active surveillance | Covered services may have deductible, coinsurance, or other plan cost sharing | Coverage and cost sharing depend on the services and care setting | Coverage and cost sharing depend on state program rules and covered services |
WHAT THE INTERVAL CHANGE MAY MEAN FOR PLAN DESIGN
The practical implication is a shift in where the decision gets made. Moving from shared decision-making language to a scheduled interval takes part of the decision out of the exam room and puts it into the plan document, because a standing recommendation creates a recurring service and a recurring coverage question. The ACS schedule identifies how often average-risk men should be tested. It does not specify which party pays for each test or whether the service counts as preventive under a particular policy.
The two-year interval is also a coverage-design signal. A plan that currently covers annual PSA testing may be paying for a test that the new ACS guideline says average-risk men need half as often. Men should confirm whether an annual test remains covered as preventive and whether utilization review may apply. The interval alone does not establish that a plan will change its benefits.
The coverage question sits alongside the guideline’s stated harms. The USPSTF estimated that 20 to 50 percent of screen-detected prostate cancers may be overdiagnosed, and about 1 percent of biopsies lead to hospitalization for complications. These estimates describe potential harms; they do not determine whether an individual should be screened.
THREE COVERAGE SITUATIONS
56-year-old self-employed contractor in Mesa, Arizona: The new schedule places this average-risk man on a PSA test every two years. On a bronze HSA-qualified Marketplace plan, the plan may apply the deductible to the lab bill because PSA screening is a C-grade service under the current USPSTF recommendation. Under the HSA-qualified plan design, the negotiated rate may be the amount owed at the counter until the deductible is met. The order’s classification should be confirmed with the plan in writing before the blood draw.
46-year-old Black man with employer coverage: The ACS schedule begins annual PSA testing at age 45 for Black men. If his employer plan is self-funded, state insurance mandates on prostate screening generally do not reach the plan. Whether the test is covered without cost sharing depends on the employer’s plan design. HR can confirm the plan’s funding status and how a screening PSA is coded.
71-year-old on a Medicare Advantage plan: Medicare pays for an annual PSA blood test, while the ACS guideline places ages 70 to 74 in a discussion window and recommends a two-year interval if screening continues. The patient can ask the clinician what follow-up a positive result could involve and check the plan’s rules for MRI and biopsy before proceeding.
MEDICARE COVERAGE
Medicare Part B covers a PSA blood test once every 12 months for men over 50. The PSA blood test itself costs nothing under the stated benefit. A DRE is covered after the Part B deductible, with 20 percent coinsurance for the exam and related doctor services. A separate hospital outpatient copayment may apply in that setting.
The schedules do not match exactly: Medicare still pays for the DRE that the new ACS guideline does not endorse as a screening test, and Medicare’s yearly PSA rhythm differs from the ACS two-year interval for average-risk men. Medicare Advantage plans must cover at least what Original Medicare covers, but network and prior-authorization rules may apply to imaging and biopsies.
PRE-TEST COVERAGE CHECKLIST
Before booking, confirm:
- Whether the recorded risk category is average risk or higher risk.
- Whether the clinician’s order is for screening or diagnostic testing.
- Whether the lab bill will be applied to the deductible.
- Whether the imaging center is in network if follow-up imaging is needed.
- The plan’s coverage and authorization policy for biomarker tests.
- Who will read the result and communicate follow-up instructions.
QUESTIONS FOR A LICENSED AGENT OR HR BENEFITS CONTACT
- Is the employer plan self-funded or fully insured?
- Does the plan treat a PSA order for an asymptomatic person as preventive, and how is it coded?
- Are the planned imaging center and pathology provider in network?
- How would a prostate biopsy be cost-shared under this plan?
- What coverage, cost sharing, or prior-authorization rules apply to a repeat PSA or biomarker test?
RECORD LIMITATIONS
The ACS guideline is a clinical recommendation, not a coverage determination. Plan documents, the Summary of Benefits and Coverage, and the clinician’s order control the applicable benefits and patient cost sharing. Available coverage may differ by state, plan type, network, coding, and medical-necessity review. The USPSTF update is pending; its final recommendation could change the federal no-cost preventive-services framework later. Information should be independently confirmed with the insurer, Medicare plan, Medicaid program, employer benefits office, and clinician before services are received.